fda drug safety communication semaglutide naion 2025 Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies U.S. FDA finds no evidence

Contact your GP or IBD team promptly if you experience worsening gastrointestinal symptoms, as distinguishing between medication side effects and a Crohn's flare requires clinical assessment

"But with all those clinical trials, if they're interested in measuring lean mass loss, they need to consider physical function." Copyright 2025 Nexstar Media, Inc

Isoliquiritigenin induces HMOX1 and GPX4-mediated ferroptosis in gallbladder cancer cells

We follow a structured process that includes product verification, batch traceability, documentation support, and coordinated delivery planning

(6) Differences in study design, statistical methodologies, and population characteristics: Even for the same drug, disparate conclusions may be derived from different studies (116, 130, 133, 134, 145)